T21 (Risedronate sodium delayed-release 35 mg)
Pill imprint T21 has been identified as Risedronate sodium delayed-release 35 mg.
Risedronate is used in the treatment of prevention of osteoporosis; osteoporosis; paget's disease and belongs to the drug class bisphosphonates. Risk cannot be ruled out during pregnancy. Risedronate 35 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- T21
- Strength:
- 35 mg
- Color:
- White
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Drug Class:
- Bisphosphonates
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Teva Pharmaceuticals USA Inc
More about risedronate
Consumer resources
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
